IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. (IDYA) priced its initial public offering on May 24, 2019 at $10.00 per share, below its $13.00–$15.00 range, raising $50M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $194.8M. J.P. Morgan was lead-left underwriter, joined by Citigroup and Jefferies. Latham & Watkins advised the company and Davis Polk advised the underwriters.

IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company developing targeted therapeutics for patient populations chosen with molecular diagnostics. It combines translational biomarker work with small molecule discovery, including drugs directed at oncogenic pathways and synthetic lethality targets.

Status

IPO

Ticker

IDYA

Exchange

Nasdaq Global Select

Priced

May 24, 2019

IPO price

$10.00

Price range

$13.00–$15.00

Raised

$50M

Market cap at IPO price

$194.8M

First filed

Apr 26, 2019

Underwriters

J.P. Morgan, Citigroup and Jefferies

Company counsel

Latham & Watkins

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.